Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
The ELPIS I data were highly encouraging and reinforce our enthusiasm for Lomecel-B as a potential treatment to transform care for patients with HLHS
Supported by data obtained from ELPIS I and CLEAR MIND, we are confident that Lomecel-B represents an important potential breakthrough for patients and an attractive value proposition for our investors
Many of them will be in Europe, but there is also a considerable amount of HLHS in Japan and other countries as well that represents a very good opportunity for the international market
And that represents a very good commercial opportunity
First, I want to say that we are extremely excited and happy with the results that we have seen out of the CLEAR MIND trial
We also took steps to strengthen our balance sheet, securing $6.4 million of gross proceeds from equity financing during the fourth quarter
As such, there is an important unmet medical need to improve right ventricular function in these patients to improve both short-term and long-term patient outcomes
We believe these results support the therapeutic potential of Lomecel-B in the treatment of mild Alzheimer’s disease and provide evidence-based support for further clinical development
We remain confident that we can launch the product in the U.S
The data that we have generated in HLHS and Alzheimer's disease all support broader potential for Lomecel-B as a regenerative medical therapy for range of unmet medical needs
In order to accelerate this, we believe that one of the best mechanisms is to share some of the best practices from the sites that has been there
Though we remain confident in the broader therapeutic potential of this asset, we believe that narrowing our focus in the near-term on HLHS is the best interest of the patients, investors and our shareholders
We are pleased speaking with you today
During this year, that's 2023, we made significant progress advancing our lead assets, Lomecel-B, to important milestones
Overall, it's excitement in the area
And I also believe there could be also with the type of data that we have presented so far, that this is going to get more people to be excited about that view
There is an option for this patient – for patients and the feedback was overwhelmingly positive
I can tell you that all the 2025, 2026 expenses will be saved in addition to a significant saving in 2024
We announced top line results from this trial in October 2023, an additional positive clinical data and MRI data results last December
Specifically, cognitive function improved as measured by MOCA, Montreal Cognitive Assessment Score, with p-value 0.05
Net loss increased to approximately $21.4 million for the year ended December 31, 2023, from a net loss of $18.8 million for the same period in 2022
The additional clinical data and MRI data we announced in December showed improvement in clinical and MRI endpoints in specific Lomecel-B growth compared to placebo
2023 was a productive year for Longeveron
As you know, HLHS even if it's addressed by the surgery, but the three stages of surgery, there are still limitations and surgeons and everybody who taken care of these patients, also looking for the opportunities to improve lives of these patients and mostly improve the long-term survival and delay or even not to have heart transplantation
HLHS is our top priority program, and we believe our most important value driver in near-term
That's certainly extremely helpful
So there is an overall excitement
Good to talk to you guys and good presentation
Yes, yes, the positive results, and like you said, it's a major problem in the United States
On behalf of Longeveron, I would like to thank you for your continued interest and support and wish you a good day today
       

Bearish Statements during earnings call

Statement
Clinical trial revenue for the year ended December 31, 2023, decreased by $0.2 million when compared to 2022 as a result of decreased participant demand
2023 revenues decreased $0.5 million or 42% when compared to 2022 as a result of decreased grant revenue and lower participant demand for our Bahamas Registry Trial
Furthermore, even those children this successful surgical intervention are at elevated trees of short-term mortality, delayed development and long-term complications, including organ failure
Brain neuroinflammation as measured by diffuse tensor imaging, DTI also diminished with p-value 0.01
The decrease of $0.2 million was primarily due to the decrease in the revenues earned from Bahamas Registry Trial and reduced direct costs associated with our Grants program
It is one of the biggest public health crisis that we have faced in recent years, and there is a lot of people who want to put money
This resulted in a gross profit of approximately $0.2 million for the year ended December 31, 2023, when compared – a decrease of $0.3 million when compared with a gross profit of $0.5 million for 2022
Research and development expenses for the year ended December 31, 2023, decreased to approximately $9.1 million from approximately $9.4 million for the same period in 2022
As you also know, that was a trial that has been going now for over 1.5 year, sometimes sites gets a fatigue
HLHS, for those who might not know, is a rare congenital and devastating birth defect in which the left the ventricle of the heart is either severely underdeveloped or missing
While these children can now live into adulthood with surgical intervention, only 50% to 60% of affected individuals survive to adolescents due to right ventricle failure, which is often unable to handle the increased load required to support systemic circulation
Babies born with this condition have severely diminished systemic blood flow which require children to undergo a complex three-stage heart reconstruction surgery process over the course of the first five years of their life
Brain MRI demonstrated whole brain volume loss slowed accompanied by significant preservation of left hippocampal volume
I had several questions
   

Please consider a small donation if you think this website provides you with relevant information